Hemogenyx Pharmaceuticals PLC Result of Annual General Meeting (2125D)

TIDMHEMO

RNS Number : 2125D

Hemogenyx Pharmaceuticals PLC

25 June 2021

25 June 2021

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

AGM Voting Results

 
 Ordinary Resolutions        Votes         % of     Votes       % of       Total votes   Total       Votes 
                              for           votes    Against     votes      cast          votes       with-held 
                                            cast                 cast                     cast as     (2) 
                                            for                  against                  % of ISC 
                                                                                          (1) 
 1. To adopt the 
  2020 Annual Report 
  and Accounts               126,557,317   99.87%   168,193     0.13%      126,725,510   12.93%      289,150 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 2. To approve 
  the Directors' 
  Remuneration Policy        125,619,330   99.07%   1,177,033   0.93%      126,796,363   12.94%      218,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 3. To approve 
  the Directors' 
  Remuneration Report        125,638,477   99.07%   1,177,033   0.93%      126,815,510   12.94%      199,150 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 4. To reappoint 
  the Company's 
  auditor                    126,528,170   99.87%   168,193     0.13%      126,696,363   12.93%      318,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 5. To authorise 
  the Audit Committee 
  to determine the 
  auditor's remuneration     126,356,107   99.72%   350,256     0.28%      126,706,363   12.93%      308,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 6. To re-elect 
  Sir Marc Feldmann 
  as a director 
  of the Company             125,895,121   99.28%   911,242     0.72%      126,806,363   12.94%      208,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 7. To authorise 
  the Directors 
  to allot equity 
  securities                 125,663,209   99.11%   1,133,154   0.89%      126,796,363   12.94%      218,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 Special Resolutions         Votes         % of     Votes       % of       Total votes   Total       Votes 
                              for           votes    against     votes      cast          votes       with-held 
                                            cast                 cast                     cast as     (2) 
                                            for                  against                  % of ISC 
                                                                                          (1) 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 8. To disapply 
  pre-emption provisions     123,047,368   97.04%   3,748,995   2.96%      126,796,363   12.94%      218,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 9. To adopt new 
  Articles of Association    125,663,209   99.27%   923,154     0.73%      126,586,363   12.92%      428,297 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 10. To adopt new 
  Articles of Association    126,014,268   99.36%   811,242     0.64%      126,825,510   12.94%      189,150 
                            ------------  -------  ----------  ---------  ------------  ----------  ----------- 
 

(1) The Company's issued share capital ("ISC") on 23 June 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.

(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   [e-mail] 
 Peter Redmond, Director                 [e-mail] 
 
                                         Tel: [phone] 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Adam Cowl 
 
                                         Tel: [phone] 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKPBNQBKDDAB

(END) Dow Jones Newswires

June 25, 2021 10:32 ET (14:32 GMT)